ABOUT THIS EVENT

Greenwich LifeSciences, Inc. (Nasdaq: GLSI), (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, rings the Nasdaq Opening Bell remotely from across the country.

Snehal S. Patel, CEO, rings the Opening Bell alongside the Company’s team in a virtual bell ringing ceremony.